Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis
- 1 May 1997
- journal article
- Published by Elsevier in Fibrinolysis and Proteolysis
- Vol. 11 (3), 121-128
- https://doi.org/10.1016/s0268-9499(97)80056-2
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasmaBlood Coagulation & Fibrinolysis, 1994
- Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibitionCardiovascular Research, 1994
- Reversible Tripeptide Thrombin Inhibitors as Adjunctive Agents to Coronary ThrombolysisJournal of Cardiovascular Pharmacology, 1993
- Designing thrombolytic agents: Focus on safety and efficacyThe American Journal of Cardiology, 1992
- Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarctionThe American Journal of Cardiology, 1990
- Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.Journal of Clinical Investigation, 1990
- Platelets and Thrombolytic TherapyNew England Journal of Medicine, 1990
- After coronary thrombolysis and reperfusion, What next?Journal of the American College of Cardiology, 1989
- The Thrombolysis in Myocardial Infarction (TIMI) TrialNew England Journal of Medicine, 1985
- Clot-Selective Coronary Thrombolysis with Tissue-Type Plasminogen ActivatorScience, 1983